xmab5574
mAbexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01161511)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mor208 monoclonal antibody
- xmab5574
- xmab5574
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01161511 | Phase 1 | Sep 1, 2010 | Augusta University, Ohio State University, SCRI Development Innovations, Xencor |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Augusta University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2010 |
| Xencor | For profit | 1 | 1 | 1 | 2010 |
4 organizations
Page 1 / 1